Phase 2 Study of Candidate for Refractory Indolent Non-Hodgkin Lymphoma Patients So-So
News
Infinity Pharmaceuticals recently announced that its Phase 2 clinical trial Dynamo evaluating the efficacy and safety of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint but ... Read more